TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05627024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% Oxygen
Description: Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 30%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Manual lung recruitment maneuvers will be performed after tracheal intubation and before tracheal extubation, however when intraoperative oxygen saturation is less than 92% the manual lung recruitment maneuver will be done too. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 60% Oxygen
Description: Before anesthesia induction, the participants inhaled pure oxygen through the mask for 5 mins. After successful anesthesia induction, Fio2 will be adjusted to 60%, and the total gas flow rate will be set at 2L/min. All patients will be performed via the lung protective ventilation strategy. The respiratory parameters are VT: 6-8ml/kg, PEEP: 6-8 cmh2O, RR: 1:2, and respiratory rate will be adjusted by maintaining a partial pressure of carbon dioxide at 35-45 mmHg. Arterial blood will be collected twice for blood gas analysis, the first once is in the non-oxygen inhalation state before anesthesia induction and the second is 30min before the end of surgery. Patients in both groups will be extubated in the operating room and then sent to the PACU.
Study: NCT04760405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi Easy
Description: Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.
Study: NCT04607746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule Endoscope
Description: Capsule endoscope used to view colonic mucosa
Study: NCT04829916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-035
Description: Multiple dosing during 48 hours following cardiac surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multiple dosing during 48 hours following cardiac surgery
Study: NCT05496569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3616 capsule
Description: TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB3616 placebo
Description: Placebo
Study: NCT05133765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Alterations in insulin pump therapy or carbohydrate consumption

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Alterations in insulin pump therapy or carbohydrate consumption

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin pump
Description: Alterations in insulin pump therapy or carbohydrate consumption
Study: NCT05264883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
Description: Treatment with Venetoclax+Decitabine/Azacitidine+Aclarubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax-Decitabine/Azacitidine Association
Description: Treatment with Venetoclax+Decitabine/Azacitidine
Study: NCT05180071

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEMA elbow system
Description: Total elbow replacement
Study: NCT06195397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-Based Education intervention
Description: A total of 12 hours of Evidence-Based Education intervention was applied to students in the intervention group, spread over 7 sessions.
Study: NCT05365204

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near infrared fluorescence navigated sentinel lymph node mapping
Description: Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near infrared fluorescence navigated sentinel lymph node mapping
Description: Patient will undergo sentinel lymph node biopsy with near infrared fluorescence navigation. The dosage of ICG will not exceed 2.5 mg in total, and the volume of the assigned solvent will not exceed 5 mL in total.
Study: NCT06049056

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
Study: NCT04935528

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serology and ELISPOT test
Description: 27 mL blood sample to study the humoral and the cellular immune response

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serology and ELISPOT test
Description: 27 mL blood sample to study the humoral and the cellular immune response
Study: NCT06049056

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,

Intervention type: OTHER
Intervention: Invitation
Description: During Recruitment Method 3, x4 practices will send letters with a URL link providing the potential participant with access to the online questionnaire, x4 practices will send letters with a QR code providing the potential participant with access to the online questionnaire, and x2 practices will send letters with a URL link and a QR code providing the potential participant with access to the online questionnaire,
Study: NCT04935528

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serology and ELISPOT test
Description: 27 mL blood sample to study the humoral and the cellular immune response

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: serology
Description: 7 mL blood sample to study the humoral response
Study: NCT06367465

Intervention type: DRUG
Intervention: Glecaprevir-pibrentasvir
Description: Glecaprevir-pibrentasvir 100 mg / 40 mg 3 tab orally (PO) once daily for 56 days.
Study: NCT05112692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone Tablets
Description: first arm will be coadministered gonadotrophins with 20mg dydrogesterone till day of trigger second arm will be subjected to fixed GnRH antagonist protocol then will do Freeze All in both arms then frozen embryo transfer next cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrorelix 0.25mg
Description: In the fixed GnRH antagonist protocol, daily s.c. administration of Cetrotide 0.25 mg will be initiated at 6th day of stimulation. HMG (150-225IU) will be administered daily from menstrual cycle day 3.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: (150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human menopausal gonadotropin
Description: (150-225IU) will be administered daily from menstrual cycle day 3 till day ot trigger

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin 0.1 mg
Description: When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m
Study: NCT06525337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STANDARDCARE (STAND) group
Description: Will receive a device and health coaching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONTROL (CON) group
Description: Will not use any devices or receive health coaching
Study: NCT05112692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triptorelin 0.1 mg
Description: When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human chorionic gonadotropin
Description: When the dominant follicles reach a diameter of 18mm, the final stage of oocyte maturation will be induced with injections of 100µg of triptorelin s.c combined with 1000IU of hCG i.m

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation
Description: All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryopreservation
Description: All of the follicles greater than 10mm in diameter will be aspirated. The oocytes are inseminated approximately 4-6hours after follicular aspiration by a conventional IVF method or intracytoplasmic sperm injection, based on the sperm quality On day 3, high quality embryos are cryopreserved by means of vitrification

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate and progesterone
Description: Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol Valerate and progesterone
Description: Endometrium will be prepared using step-up oral estrogen protocols. On day 14 of estrogen administration, endometrial thickness will be assessed and serum progesterone level will be measured, with cycles to be cancelled according to the arbitrary thresholds of 7.0 mm and 1.5 ng/mL, respectively. Progesterone administration will be started on the morning (am) of day 15, with the start date of progesterone and the day of blastocyst cryopreservation used to coordinate the day of FET
Study: NCT05771181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Vitamin E: 400mg (QD), oral, once daily, continued until disease progression or intolerable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fuquinitinib: 5mg (QD) orally for 2 weeks, 1 week off, repeated every 3 weeks until disease progression or intolerable toxicity.
Study: NCT05635110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.
Study: NCT06337799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Research Pharmacist
Description: The goal of this intervention is to determine if allied health professionals will improve blood pressure in new mothers.
Study: NCT05635110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-548
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Tablets for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Capsules for oral administration.
Study: NCT05893693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological
Description: CT0594CP
Study: NCT04839900

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Proactive iCCM
Description: CHWs in the proactive iCCM intervention arm will conduct weekly visits of all households in their communities to detect children \< 5 years with diarrhea or cough, and people of all ages complaining of fever or history of fever. People with fever or history of fever in the past 48 hours, or any person with symptoms suggestive of malaria (chills, headache, muscle ache, fatigue, etc), will receive an RDT; those with positive results will be defined as confirmed malaria cases, and will receive the first line antimalarial. Any child under 5 years with diarrhea will be treated with oral rehydration solution (ORS) and zinc, and any child meeting diagnostic criteria for pneumonia will receive the first line antibiotic recommended per national iCCM policy. If the CHW does not have the indicated therapy on hand, the patient will be referred for treatment.
Study: NCT05579600

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caring Contacts letters
Description: Caring Contacts involves sending individuals at risk for suicide brief, non- demanding messages of care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reports, re-engagement, and training
Description: Behavioral health providers will receive training in reaching out to and re- engaging patients who pass through the justice system, as well as training in suicide risk assessment (the Columbia Suicide Severity Rating Scale; C-SSRS) and response (the Safety Planning Intervention; SPI).
Study: NCT05771181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Tislelizumab: 200mg intravenously every 3 weeks (Q3W), was administered until the occurrence of unacceptable toxic effects, or disease progression, withdrawal of consent, or withdrawal as judged by the investigator.
Study: NCT05472558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-NK
Description: lentiviral vector-transducted cord blood-derived NK cells to express anti-CD19 CAR
Study: NCT05700552

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: skin to skin contact
Description: For skin-to-skin contact (TTT), the newborn is placed naked on the mother's bare chest in the prone (prone) position, the newborn's abdomen and chest are in contact with the mother's skin, and the newborn's head is turned to the side so that the airway remains open.
Study: NCT06394869

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cxbladder Detect+
Description: Cxbladder Detect+ is a lab developed, test that is using RNA and DNA biomarkers in the urine to assess the likelihood of the presence of urothelial carcinoma in the bladder.
Study: NCT05992506

Intervention type: DIAGNOSTIC_TEST
Intervention: POD risk estimation using PEUMA
Description: A software will analyze intraoperative EEG recording for the estimation of a POD Risk Index
Study: NCT05826964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI+CDK4/6i
Description: Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI+CDK4/6i
Description: Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI+CDK4/6i
Description: Participants will receive standard of care one of three available AI therapies in combination with one of three available CDK4/6i therapies:~* AI: Anastrozole, Letrozole or Exemestane~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERD+CDK4/6i
Description: Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERD+CDK4/6i
Description: Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SERD+CDK4/6i
Description: Participants will receive standard of care SERD therapy in the form of Fulvestrant, in combination with one of three one of three available CDK4/6i therapies:~* SERD: Fulvestrant~* CDK4/6i: Palbociclib, Ribociclib or Abemaciclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor + AI
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mTOR inhibitor + AI
Description: Participants will receive standard of care mTOR inhibitor therapy (Everolimus) in combination with AI therapy (Exemestane) in Step 2 Arm 2 and Step 3. mTOR inhibitor + AI therapy administered as one of the available options for early switch from AI+CDK4/6i or SERD+CDk4/6i therapy in administered in Step 1.
Study: NCT05719155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-379
Description: 1 tablet administration under fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D759+D745+D150
Description: 3 tablet coadministration under fed condition
Study: NCT05077735

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation Therapy
Description: Undergo hypofractionated radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography and Computed Tomography Scan
Description: Undergo PET-CT scan